Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

Description

To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.

Conditions

Transplant Complication

Talk to us

Study Overview

On this page

Study Details

Study overview

To develop a prospective quantitative liver allograft monitoring protocol and retrospectively validate the use of Phenotypic personalized medicine (PPM) in immunosuppression dosing in liver transplant recipients.

Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

Condition
Transplant Complication
Intervention / Treatment

-

Contacts and Locations

Gainesville

University of Florida, Gainesville, Florida, United States, 32608

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * At least 18 years of age
  • * At least one-month post-transplant
  • * Recipient of a liver transplant alone or a simultaneous liver-kidney transplant
  • * Unwilling to provide informed consent
  • * Recipient of a previous bone marrow or stem cell transplant
  • * Pregnant
  • * Unlikely to be able to comply with the study requirements, as determined by the PI

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Florida,

Study Record Dates

2025-10-15